Amgen Inc Call from European Society for Medical Oncology 2021 Congress Transcript
My name is Christie, and I will be your conference facilitator today for Amgen's Conference Call from the European Society for Medical Oncology 2021 Virtual Congress. (Operator Instructions)
I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.
Thank you, Christie. Good morning, everyone. Thanks for joining us this morning.
So we presented important data at the ESMO meeting yesterday, looking at a combination of our KRAS G12C inhibitor LUMAKRAS with our EGFR inhibitor Vectibix, or panitumumab, in advanced colorectal cancer. We continue to lead with the largest and most comprehensive development program in patients with the KRAS G12C mutation. We look forward to going through this data in additional detail this morning, and we'll also use this opportunity to discuss our broader emerging oncology portfolio.
Joining me this morning are Dr. David Reese, our Executive Vice President of R&D; and Dr. PK Morrow, our Vice President for Global
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |